Inhaled insulin has arrived
Diabetics who are tired of daily insulin shots potentially have reason to celebrate. Sanofi and Mannkind have just launched Afrezza, an inhalable insulin therapy.
The drug was approved for patient use last June, and it may now be a viable option for people with type 1 or type 2 diabetes.
-
Sell Your Test Strips for Cash
Sell Your Test Strips With Confidence. We Offer Top Prices, Free Shipping, Fast Payments.
www.assistdiabetics.com
See It Now -
We Buy Your Unused Test Strips
Do You Have Unused Diabetes Test Strips? Get Cash Fast For Your Test Strips. Earn Money Today.
www.assistdiabetics.com/sell/test/strips
See It Now
A similar product called Exubera was approved in 2006, but it didn't go over well with patients as it required periodic lung health tests and was somewhat "bulky," reports Reuters.
Afrezza comes in a smaller device and helps to rapidly disperse insulin into the blood stream.
"You can basically plan around your day, rather than planning around your insulin," Stefan Schwarz, Sanofi's head of Afrezza's U.S. marketing, said in an interview.
Cost for Afrezza is significantly higher than injectable insulin
According to Sanofi, Afrezza should cost about $7.50 to $9.25 per day for a typical patient, which is significantly more than many injectable insulin varieties.
But the benefits may outweigh the price tag; the inhaler doesn't need cleaning and dispenses insulin through units, making dosage tracking easy for patients.
The device needs to be replaced every 15 days.
"This is an alternative for those patients who are not willing to inject insulin," Schwarz said.
Image courtesy of marin/FreeDigitalPhotos.net
Get a Free Diabetes Meal Plan
Get a free 7-Day Diabetes Meal Plan from Constance Brown-Riggs who is a Registered Dietitian-Certified Diabetes Educator and who is also a national spokesperson for the American Dietetic Association.
Just enter in your email below to download your free Diabetes Meal Plan.